Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899480 · ClinicalTrials.gov registry record · Phase 1
Adoptive Transfer of Haploidentical NK Cells and N-803
A Phase 1 study of HIV Infections and HIV, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT03899480: Completed Phase 1 study of HIV Infections and HIV, sponsored by University of Minnesota.
NCT03899480 is a Phase 1 study of HIV Infections and HIV that has completed, run by University of Minnesota. The registered enrollment target is 9 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899480, a Phase 1 study of HIV Infections and HIV, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.
Primary Outcome
Toxicity and adverse events will be classified according to Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events v2.0. Scale ranges from grade 0 to 4 with a grade of 0 indicating normal signs and symptoms and a grade of 4 indicating potentially life-threatening signs and symptoms. Grade 2, 3, and 4 adverse events will be considered when determining the safety and tolerability of treatment.
Conditions Studied
Interventions
- BIOLOGICAL Haploidentical Natural Killer (NK) Cells
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 1 |
What the finished NCT03899480 record still lists
NCT03899480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Haploidentical Natural Killer (NK) Cells is the first listed.
NCT03899480 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03899480 about?
NCT03899480 is a clinical study titled "Adoptive Transfer of Haploidentical NK Cells and N-803". This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.
What is the current status of trial NCT03899480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-05-01. Estimated completion is 2021-04-01.
What conditions does trial NCT03899480 study?
This clinical trial studies the following conditions: HIV Infections, HIV, Immune Deficiency.
What interventions are being tested in trial NCT03899480?
The interventions under investigation include: Haploidentical Natural Killer (NK) Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03899480?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899480 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03899480's enrollment target sits among peer trials
9 530th of 542 higher than 11 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI